- Home
- ASMB vs BLUE Comparison
ASMB vs BLUE Comparison
Compare ASMB & BLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASMB
- BLUE
- Stock Information
- Founded
- ASMB 2005
- BLUE 1992
- Country
- ASMB United States
- BLUE United States
- Employees
- ASMB N/A
- BLUE N/A
- Industry
- ASMB Biotechnology: Pharmaceutical Preparations
- BLUE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ASMB Health Care
- BLUE Health Care
- Exchange
- ASMB Nasdaq
- BLUE Nasdaq
- Market Cap
- ASMB 92.1M
- BLUE 75.8M
- IPO Year
- ASMB 2010
- BLUE 2013
- Fundamental
- Price
- ASMB $13.61
- BLUE $6.99
- Analyst Decision
- ASMB Buy
- BLUE Hold
- Analyst Count
- ASMB 2
- BLUE 9
- Target Price
- ASMB $35.00
- BLUE $49.14
- AVG Volume (30 Days)
- ASMB 25.5K
- BLUE 199.3K
- Earning Date
- ASMB 03-27-2025
- BLUE 03-25-2025
- Dividend Yield
- ASMB N/A
- BLUE N/A
- EPS Growth
- ASMB N/A
- BLUE N/A
- EPS
- ASMB N/A
- BLUE N/A
- Revenue
- ASMB $28,326,000.00
- BLUE $53,120,000.00
- Revenue This Year
- ASMB $282.16
- BLUE $145.88
- Revenue Next Year
- ASMB N/A
- BLUE $239.89
- P/E Ratio
- ASMB N/A
- BLUE N/A
- Revenue Growth
- ASMB N/A
- BLUE 144.50
- 52 Week Low
- ASMB $9.84
- BLUE $5.80
- 52 Week High
- ASMB $19.93
- BLUE $38.40
- Technical
- Relative Strength Index (RSI)
- ASMB 39.96
- BLUE 39.64
- Support Level
- ASMB $13.76
- BLUE $7.25
- Resistance Level
- ASMB $14.67
- BLUE $8.22
- Average True Range (ATR)
- ASMB 0.72
- BLUE 0.53
- MACD
- ASMB -0.09
- BLUE -0.11
- Stochastic Oscillator
- ASMB 2.03
- BLUE 8.81
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
About BLUE bluebird bio Inc.
bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases.